【摘要】 目的 探析达格列净与恩格列净分别联合沙库巴曲缬沙坦钠片对糖尿病伴心力衰竭（heart failure, HF的疗效。方法 选择2020年7月—2022年8月福州市长乐区医院收治的60例糖尿病伴HF患者，采用随机数表法分为观察组（n=30）、对照组（n=30）。两组均给予沙库巴曲缬沙坦钠片治疗，对照组联合达格列净，观察组联合恩格列净。对比两组治疗前后的血糖参数、心功能参数、随访6个月后的全因病死率及HF再入院率、用药相关不良反应。结果 治疗后，两组各项心功能参数水平对比，差异无统计学意义（P>0.05）。治疗后，观察组各项血糖参数均低于对照组，差异有统计学意义（P<0.05）。两组糖尿病伴HF患者全因病死率、用药相关不良反应总发生率对比，差异无统计学意义（P>0.05）。观察组HF再入院率低于对照组，差异有统计学意义（P<0.05）。结论 相较于达格列净，恩格列净联合沙库巴曲缬沙坦钠片应用于糖尿病伴HF患者中临床效果显著，可有效改善患者血糖控制水平及心功能指标，降低HF再入院率，且联合用药安全性较高。更多还原

【Abstract】 Objective To investigate the efficacy of dapagliflozin and empagliflozin combined with sacubitril valsartan sodium tablets respectively in diabetes mellitus with heart failure(HF). Methods Sixty patients with diabetes mellitus and HF treated in Fuzhou Changle District Hospital from July 2020 to August 2022 were selected and divided into observation group(n=30) and control group(n=30) by random number table method. Both groups were given sacubactril and valsartan sodium tablets, control group combined with dagliprazin, observation group combined with engliprazin.Blood glucose parameters, cardiac function parameters, all-cause mortality, HF readmission rate and drug-related adverse reactions after 6 months of follow-up were compared between the two groups before and after treatment. Results There was no statistically significant difference in the level of cardiac function parameters between the two groups after treatment(P>0.05). After treatment, all blood glucose parameters in the observation group were lower than those in the control group, and the difference was statistically significant(P<0.05). There was no statistically significant difference in the all-cause mortality and the total incidence of drug-related adverse reactions between the two groups(P>0.05). The HF readmission rate of observation group was lower than that of control group, and the difference was statistically significant(P<0.05). Conclusion Compared with dapagliflozin, the application of engeletin combined with sacubitril valsartan sodium tablets in patients with diabetes mellitus with HF is clinically effective, which can effectively improve the level of blood glucose control and cardiac function indexes of the patients, and reduce the rate of HF readmission, and the safety of the combined use of medication is high.更多还原